PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Vir Biotechnology's PE Ratio without NRI is 0.00. Vir Biotechnology's 5-Year EBITDA growth rate is 0.00%. Therefore, Vir Biotechnology's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Vir Biotechnology's PEG Ratio or its related term are showing as below:
VIR's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.435 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Vir Biotechnology PEG Ratio Historical Data
The historical data trend for Vir Biotechnology's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vir Biotechnology's PEG Ratio
For the Biotechnology subindustry, Vir Biotechnology's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology's PEG Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's PEG Ratio falls into.
Vir Biotechnology PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
Vir Biotechnology's PEG Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Vir Biotechnology (NAS:VIR) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Vir Biotechnology PEG Ratio Related Terms
Thank you for viewing the detailed overview of Vir Biotechnology's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Vir Biotechnology (Vir Biotechnology) Business Description
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIR has been successfully added to your 